The Authors' reply
- PMID: 33172914
- DOI: 10.1136/heartjnl-2020-318314
The Authors' reply
Keywords: epidemiology.
Conflict of interest statement
Competing interests: JH-C reports grants from the National Institute for Health Research Biomedical Research Centre, Oxford, grants from John Fell Oxford University Press Research Fund, grants from Cancer Research UK (CRUK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre, and grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z), during the conduct of the study; personal fees and other from ClinRisk (until 2019), outside the submitted work; and is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health, which supply the QResearch database used for this work. PST reports consulting with AstraZeneca and Duke-NUS, outside the submitted work.
Comment on
-
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.Heart. 2020 Oct;106(19):1503-1511. doi: 10.1136/heartjnl-2020-317393. Epub 2020 Jul 31. Heart. 2020. PMID: 32737124 Free PMC article.
-
Antihypertensive drugs and COVID-19.Heart. 2021 Jan;107(1):85. doi: 10.1136/heartjnl-2020-318313. Epub 2020 Nov 10. Heart. 2021. PMID: 33172913 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources